Rheumatologists Narrow Focus on Select SLE Therapies as Pipeline Clarity Emerges

Event summary

  • Q4 2025 Market Dynamix™: SLE Pipeline Refresh shows rheumatologists shifting from broad enthusiasm to selective, indication-driven expectations for late-stage SLE therapies.
  • Gazyva (Roche/Genentech) gains traction post-lupus nephritis approval, with nearly 50% of rheumatologists expecting it to reshape treatment pathways.
  • Rinvoq (AbbVie) maintains strong positioning but sees estimated patient candidacy decline to mid-teens due to JAK class safety concerns.
  • Ianualumab (Novartis) stands out for broad perceived efficacy across SLE manifestations, positioning it as a potential competitor to established biologics.
  • Enthusiasm moderates for Litifilimab (Biogen) and Dapirolizumab Pegol (Biogen/UCB) due to unanswered safety and efficacy questions.

The big picture

The SLE pipeline is maturing with rheumatologists now favoring therapies with distinct clinical roles, reflecting a shift from broad enthusiasm to targeted adoption. This trend underscores the challenges of developing therapies for a disease marked by complex biology and heterogeneous presentation. The current pipeline, however, shows sustained innovation potential to reshape SLE management, with key assets like Gazyva and ianalumab emerging as leaders in specific patient segments.

What we're watching

Therapeutic Differentiation
How the increasing stratification of SLE therapies will impact adoption rates and market share.
Safety Concerns
Whether JAK class safety considerations will further temper enthusiasm for oral advanced therapies.
Clinical Trial Success
The pace at which late-stage assets like ianalumab can demonstrate long-term safety and durability of response.